Uncategorized

Estrigenix Therapeutics Announces Series Seed Financing to Advance ERβ Platform Across Women’s Health and Neurodegenerative Diseases

Estrigenix Therapeutics Announces Series Seed Financing to Advance ERβ Platform Across Women's Health and Neurodegenerative Diseases

MILWAUKEE (July 21, 2026) — Estrigenix Therapeutics today announced the first closing of its $2M Series Seed financing, led by Talents Fund I. The financing provides the resources to advance its proprietary selective estrogen receptor-beta (ERβ) platform through translational preclinical development. The announcement follows several recent milestones in the company’s evolution, including completion of its … Estrigenix Therapeutics Announces Series Seed Financing to Advance ERβ Platform Across Women’s Health and Neurodegenerative Diseases

Estrigenix Therapeutics Secures Exclusive License Agreement for Novel Menopause Therapeutics Platform

MILWAUKEE (June 30, 2026) — Estrigenix Therapeutics, Inc., together with the University of Wisconsin–Milwaukee Research Foundation, Inc. (UWMRF), Marquette University, and CU Ventures, Inc., today announced the execution of an exclusive license agreement supporting the development of a novel therapeutic platform designed to address the mental and physical effects of menopause. Under the terms of the … Estrigenix Therapeutics Secures Exclusive License Agreement for Novel Menopause Therapeutics Platform

Estrigenix Therapeutics, Inc. presents at 2nd ACE Drug Discovery Summit 2024 in London

MILWAUKEE (March 21, 2024) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is proud to have been a presenter at the ACE Drug Discovery Summit 2024 in London. William Donaldson, Ph.D., chief executive officer (CEO) of Estrigenix presented an abstract entitled, “Discovery of Selective Estrogen Receptor Beta … Estrigenix Therapeutics, Inc. presents at 2nd ACE Drug Discovery Summit 2024 in London

Estrigenix invited to present at the Science2Startup Symposium in Boston, April 10th

MILWAUKEE (March 8, 2024) – Estrigenix Therapeutics, Inc., was selected to speak at Science2Startup symposium in Boston on April 10th. The Symposium is an invitation-only event focused on bringing academic innovations to the attention of the Boston-based venture capital ecosystem. Estrigenix was selected as one of eight teams to present, out of over 132 submissions. … Estrigenix invited to present at the Science2Startup Symposium in Boston, April 10th

CSO Karyn Frick discusses “Why women are more likely to develop Alzheimer’s Disease” on Chicago radio WLS 890AM (the Big 89)

MILWAUKEE (October 25, 2023) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company is leading the way in estrogen biology. Karyn Frick, Ph.D, chief scientific officer of Estrigenix spoke with Rob Johnson and Jane Clauss of Chicago radio “The Big 89” regarding Alzheimer’s Disease and the increased risk for women developing AD. It has … CSO Karyn Frick discusses “Why women are more likely to develop Alzheimer’s Disease” on Chicago radio WLS 890AM (the Big 89)

Estrigenix Therapeutics to Attend The Menopause Society Meeting

MILWAUKEE (Sept. 22, 2023) – Estrigenix Therapeutics, Inc., is announcing Patricia Scheller, Executive Chairwoman, and Daniel Sem, VP for Business Development will attend the The Menopause Society, (formerly known at the North American Menopause Society) Annual Meeting in Philadelphia September 27 – 30, 2023. The Menopause Society is the premier organization for health professionals with … Estrigenix Therapeutics to Attend The Menopause Society Meeting

Estrigenix welcomes new employees

Estrigenix Therapeutics welcomed two new employees this summer, Ms. Elaina Milkie and Dr. Dulanjali Thennakoon. Ms. Elaina Milkie graduated with B.S. from the University of Wisconsin-Milwaukee (UWM) in May 2023, double majoring in Psychology and Biological Sciences. Elaina worked part time with Estrigenix in spring 2023 while completing her degree and transitioned to full time … Estrigenix welcomes new employees

Estrigenix Therapeutics one of five Wisconsin companies awarded SBIR Advance Phase 1 funding from WEDC

Estrigenix Therapeutics was one of five Wisconsin-based companies awarded matching funding from the SBIR Advance Phase 1 program funded by the Wisconsin Economic Development Corporation. The SBIR Advance program provides assistance to companies in the process of completing a project in the federal Small Business Innovation Research (SBIR) program. feedback and reviewed multiple proposals from … Estrigenix Therapeutics one of five Wisconsin companies awarded SBIR Advance Phase 1 funding from WEDC

Estrigenix Therapeutics, Inc. presents at Precision Drug Discovery & Preclinical Summit 2023 in Boston

MILWAUKEE (June 15, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is proud to have been a presenter at the Precision Drug Discovery & Preclinical (PDDP) Summit 2023 in Boston. William Donaldson, Ph.D., chief executive officer (CEO) of Estrigenix presented an abstract entitled, “Discovery of Selective … Estrigenix Therapeutics, Inc. presents at Precision Drug Discovery & Preclinical Summit 2023 in Boston

Estrigenix CSO Karyn Frick Featured on “FemTech Focus” Podcast

MILWAUKEE (May 16, 2023) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, was recently featured on the podcast FemTech Focus hosted by Brittany Baretto, PhD. Karyn Frick, Ph.D, chief scientific officer of Estrigenix spoke with Dr. Baretto regarding Estrigenix’s first-in-class therapeutics to treat and prevent hot flashes … Estrigenix CSO Karyn Frick Featured on “FemTech Focus” Podcast